Experts at MMS have reviewed COVID-19 guidance documents and taken into account the current state of clinical research globally to ensure our services align with these new challenges, whether those sponsors be virtual or large firms with treatments for common illnesses or rare conditions. What has been identified in this whitepaper are key areas of change faced by the industry.
by Jessica Alamdari, April 3, 2020
During these unprecedented times, many businesses are struggling to continue business as usual while the world is rapidly changing around them; however, certain businesses continue to thrive. Throughout this COVID-19 pandemic, companies like MMS, among other leaders in the pharmaceutical industry, are not only carrying out typical day-to-day business operations, but they are well-positioned to offer additional support to companies unable to adapt.
by Staff Writer, March 25, 2020
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from March 2020.
by Staff Writer, March 17, 2020
In this Expert Insights interview, we sit down with Dr. Uma Sharma, Chief Scientific Officer at MMS Holdings. Dr. Sharma discusses her thoughts surrounding the Circle of Concern and the Circle of Influence, including how it influences the culture at MMS.
by Staff writer
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. February’s news includes coronavirus vaccine development, saving 7 million lives from cancer, and more.
by Aaron Robert, February 7, 2020
The pharmaceutical industry—and healthcare in general—are in constant stages of innovation. According to the International Federation of Pharmaceutical Manufacturers & Associations, the number of new chemical or biological entities launched on the world market stood at 226 from the years 2011 to 2015, a 35 percent increase from the decade prior.
by Staff Writer
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from November 2019.
by Staff Writer
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection from October 2019…
Webinar: The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare
by MMS Holdings and MichBio.org
This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in drug development, from the perspective of a clinical trial programmer/data analyst. We will discuss the potential opportunities that can generate RWD to improve the safety, efficiency, and quality in a clinical paradigm.
Each month, MMS shares key stories on the evolution of the pharmaceutical industry. Here is a selection of top stories to keep an eye on in September 2019: FDA Developing Guidance on Real-World Data Quality Issues, Officials Say.